

ZANUBRUTINIB PLUS OBINUTUZUMAB VS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY

Authors:

Alejandro Martin Garcia-Sancho,¹ Ana C. de Oliveira,² Mariano Provencio Pulla,³ Pier Luigi Zinzani,⁴ Jiří Mayer,⁵ Christopher R. Flowers,⁶ Fontanet Bijou,⁷ Krimo Bouabdallah,⁸ Roderick Johnson,⁹ Marek Trněný,¹⁰ Herve Tilly,¹¹ Wojciech Jurczak,¹² Elena Ivanova,¹³ Pil Kim,¹³ Adam Greenbaum,¹³ Sha Huang,¹³ Richard Delarue,¹³ Rebecca Auer,¹⁴ Judith Trotman¹⁵

Affiliation:

¹Hospital Universitario de Salamanca, Salamanca, Spain; ²Institut Català d'Oncologia (ICO) Hospital Duran i Reynals, Barcelona, Spain; ³Hospital Universitario Puerta de Hierro — Majadahonda, Madrid, Spain; ⁴Institute of Hematology "Seràgnoli", University of Bologna, Bologna, Italy; ⁵Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic; ⁶Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX, USA; ⁷Institut Bergonié, Bordeaux, France; ⁸Hôpital Haut-Lévêque, CHU Bordeaux, Pessac, France; ⁹St James's University Hospital Trust, Leeds, UK; ¹⁰Všeobecná fakultní nemocnice v Praze, Prague, Czech Republic; ¹¹Centre Henri-Becquerel, Rouen, France; ¹²Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland; ¹³BeiGene (Shanghai) Co, Ltd, Shanghai, China, and BeiGene USA, Inc, San Mateo, CA, USA; ¹⁴St Bartholomew's Hospital, Barts Health NHS Trust, London, UK; ¹⁵Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia

Introduction: In an early-phase study, the combination of zanubrutinib plus obinutuzumab (ZO) was well tolerated and showed an early signal of efficacy in patients with follicular lymphoma (FL) (Tam et al. *Blood Adv.* 2020). ROSEWOOD (NCT03332017) is a phase 2, randomized study designed to assess the efficacy and safety of ZO vs obinutuzumab (O) in patients with relapsed/refractory (R/R) FL.

Aim: To present an updated analysis from ROSEWOOD with a median follow-up of 20.2 months.

Methods: Patients with R/R FL (grade 1-3a) who received ≥ 2 lines of therapy including an anti-CD20 antibody and alkylating agent were randomized 2:1 to receive ZO or O. Zanubrutinib was given at 160 mg twice daily until progression or unacceptable toxicity. The primary endpoint was overall response rate (ORR) by independent central review. Other endpoints included duration of response (DOR), progression-free survival (PFS), overall survival, and safety. Time to next treatment was also assessed.

Results: A total of 217 patients were randomized (ZO, n=145; O, n=72). Median age was 64 years. Median number of prior lines of therapy was 3 (range, 2-11). Most patients (52.5%) were refractory to rituximab; 98.6% of patients had received prior immunochemotherapy. The ORR was 69.0% (ZO) vs 45.8% (O) ($P=.0012$). DOR rate at 18 months was 69.3% (ZO) vs 41.9% (O), and median PFS was 28.0 months (ZO) vs 10.4 months (O) (hazard ratio, 0.50; 95% CI, 0.33-0.75; $P=.0007$). Additional efficacy results are shown in the **Table**. Nonhematologic treatment-emergent adverse events of any grade that occurred more frequently with ZO vs O ($>5\%$ difference) were petechiae and herpes zoster infection (6.3% vs 0% for both); pyrexia (13.3% vs 19.7%) and infusion-related reactions (2.8% vs 9.9%) occurred more frequently in patients receiving O. When adjusted for duration of treatment exposure, incidences of infection and cytopenia were similar, and the incidence of all grades of hemorrhage was 2.4 (ZO) vs 1.3 (O) persons per 100 person-months.

Conclusion: ZO demonstrated meaningful efficacy and a manageable safety profile in patients with heavily pretreated R/R FL and represents a potential novel therapy.

Table. Efficacy Results

	ZO	O	HR (95% CI)	2-sided P value
Primary endpoint				
ORR by ICR, %	69.0	45.8	-	.0012
Other endpoints				
Complete response rate by ICR, % ^a	39.3	19.4	-	.0035
18-month DOR rate by ICR, % ^a	69.3	41.9	-	
PFS by ICR, median, months ^a	28.0	10.4	0.50 (0.33-0.75)	.0007
TTNT, median, months	NE	12.2	0.34 (0.22-0.52)	<.0001
OS, median, months ^a	NE	34.6	0.62 (0.35-1.07)	.0845
24-month OS rate, % ^a	77.3	71.4	-	-
DOR, duration of response; HR, hazard ratio; ICR, independent central review; NE, not estimable; O, obinutuzumab; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; TTNT, time to next treatment; ZO, zanubrutinib plus obinutuzumab. ^a Secondary endpoint.				